United Therapeutics CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Martine A. Rothblatt has increased her beneficial ownership of United Therapeutics Corp. common stock to 5.3%, holding 2,333,721 shares.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.19% of United Therapeutics Corp's common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reports 0% beneficial ownership in United Therapeutics Corp following an internal realignment.
NASDAQ
Wellington Management Group LLP and its affiliates have reported a 5.67% beneficial ownership stake in United Therapeutics Corporation common stock.
NASDAQ
Wellington Management Group LLP and its affiliates have disclosed a 4.5% beneficial ownership stake in United Therapeutics Corporation, held in the ordinary course of business.
NASDAQ
Wellington Management Group LLP and its affiliated entities have reported a 5.5% beneficial ownership stake in United Therapeutics Corporation as of December 31, 2024.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting a 4.9% beneficial ownership stake in United Therapeutics Corp as of December 31, 2024, held for passive investment purposes.